An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
NCT01442064
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
608
Enrollment
INDUSTRY
Sponsor class
Conditions
Macular Edema
Retinal Vein Occlusion
Interventions
DRUG:
Ranibizumab 0.5 mg
Sponsor
Genentech, Inc.